Search results
Earnings call: Co-Diagnostics Q1 2024 financial results and updates By Investing.com
Investing.com· 2 hours agoThe company highlighted strategic developments, including nearing completion of their 510(k)...
UK NICE backs Exact’s Oncotype cancer genomic test
Medical Device Network via Yahoo Finance· 6 hours agoThe UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Exact Sciences’s genomic test Oncotype DX breast recurrence...
CLOUD DX Signs Multi-Year Contract with Provincial Health Authority
Digital Journal· 3 days agoThis agreement is the 4th Provincial Health Authority contract for Cloud DX remote patient monitoring (RPM) services, alongside Alberta, the Yukon and Prince Edward Island ...
Indica Labs Receives First FDA Clearance for HALO AP Dx Digital Pathology Platform
The Kansas City Star· 2 days agoHALO AP Dx brings digital primary diagnosis to anatomic pathology labs in the US.
AI chip startup DEEPX secures $80M Series C at a $529M valuation
TechCrunch· 20 hours agoThe Series C funding, which brings its total raise to around $95 million, will go toward mass...
Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
The West Side Index & Gustine Press-Standard· 23 hours agoSALT LAKE CITY, May 9, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx," or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular
DEEPX raises $80.5M in fresh funding to mass produce its AI chips - SiliconANGLE
SiliconANGLE· 43 minutes agoDEEPX Co. Ltd., a South Korean developer of artificial intelligence chips, has raised $80.5 million...
DX for Ship Design: Aiming to Reduce Construction Time, Costs
MarineLink· 2 days agoNippon Yusen Kabushiki Kaisha (NYK) and its group company MTI Co., Ltd. (MTI), in collaboration with...
Exact Sciences Corp (EXAS) Q1 2024 Earnings: Revenue Growth Amidst Increased Net Loss
GuruFocus.com via Yahoo Finance· 3 hours agoThe Madison, Wisconsin-based company, known for its innovative cancer screening and diagnostic tests such as Cologuard and Oncotype DX, reported a revenue of $638 million, ...
...Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of...
Benzinga· 3 days agoThe KOL event, "Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab...
